Predicine to Present 9 Liquid Biopsy Studies at ASCO 2024
2024年5月22日 - 1:11PM
Predicine, Inc. A leading precision oncology company, announced
today that it will present data from
9 ctDNA studies at ASCO 2024, spotlighting the
clinical utility of Predicine’s genomic and epigenomic liquid
biopsy solutions for patient selection, disease monitoring, and
drug resistance mechanism studies.
The forthcoming data represents significant potential for the
practical application of Predicine’s cutting-edge liquid biopsy
technology in personalized cancer care, clinical trials, and
Companion Diagnostic (CDx) development.
Numerous studies to be unveiled at the conference emphasize the
distinct advantages of personalized PredicineBEACON™ and
methylation-based PredicineALERT™ MRD underscoring the clinical
utility of Predicine’s liquid biopsy portfolio in biomarker
discovery, therapy selection, MRD monitoring, and drug resistance
mechanism analyses.
| Predicine
Oral Presentation |
|
|
Presenter |
Title |
Product |
| |
|
|
| Saturday, June 1 |
1:30 pm – 4:30 pm |
| |
|
|
| Jian Li |
A phase 1 study of the
small-molecule PD-L1 inhibitor INCB099280 in select advanced
solid tumors: Updated safety, efficacy, and pharmacokinetics (PK)
results. |
PredicineCARE™ |
| Full List
of Predicine Presentations |
|
Abstract Poster Title |
Product |
|
Saturday, June 1 | 9:00 am – 12:00 pm |
|
2053 |
352 |
Glioma monitoring via longitudinal intracranial cerebrospinal
fluid cell-free DNA. |
PredicineCARE™PredicineSCORE™ |
| |
|
|
|
| |
|
|
|
| |
|
|
|
|
Sunday, June 2 | 9:00 pm – 12:00 pm |
| 2608 |
87 |
Clinical utility of an
ultra-sensitive ctDNA NGS assay for the detection and
monitoring in HR-positive, HER2-negative breast cancer. |
PredicineCARE™ Ultra |
| |
|
|
|
| e16604 |
- |
Non-invasive detection of
urothelial carcinoma through ensembled methylation
profiles and fragmentomic patterns in urinary cell-free
DNA. |
PredicineEPIC™ |
| |
|
|
|
| e16602 |
- |
Real-world study of urine-based
NGS liquid biopsy in organ preservation therapy
of muscle-invasive bladder cancer (MIBC). |
PredicineBEACON™PredicineALERT™ |
| |
|
|
|
| e12654 |
- |
Prognostic significance of ctDNA
mutation analysis in patients with HER2-positive breast cancer
undergoing neoadjuvant chemotherapy. |
PredicineBEACON™ |
| e13076 |
- |
Phase 1 study of NB003, a
broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced
gastrointestinal stromal tumors (GIST). |
PredicineCARE™ |
| |
|
|
|
| Monday, June 3 | 1:30
pm – 4:30 pm |
| 8587 |
451 |
High-dose furmonertinib in
patients with EGFR-mutated non-small cell lung cancer and
leptomeningeal metastases: A real-world study. |
PredicineEPIC™ |
|
4600 |
295 |
Tumor fraction and copy number burden from urinary cell-free tumor
DNA (utDNA) to predict minimal residual disease prior to
repeat-transurethral resection in high-risk non-muscle invasive
bladder cancer (HR-NMIBC). |
PredicineBEACON™ |
|
|
|
|
|
Visit Predicine Booth #14105 at ASCO
2024!
Participate in conversations surrounding these groundbreaking
studies and explore collaboration opportunities. Our liquid biopsy
solutions are designed to be accessible and affordable for global
clinical trials, CDx development, and patient testing across the
US, EU, China, and the rest of world.
Click here to arrange an in-person meeting with the Predicine
team at ASCO booth #14105 or click here to schedule an online
meeting. To learn more about Predicine, please see our corporate
brochure, product portfolio, and visit our website.
About Predicine
Predicine is a leading molecular insights company
committed to advancing precision medicine in oncology. Predicine
has developed a proprietary cell-free DNA and cell-free RNA-based
liquid biopsy technology enabling minimally invasive molecular
diagnosis for treatment selection, therapy monitoring, and minimal
residual disease and early cancer detection. The Predicine
portfolio comprises state-of-the-art blood, urine, and tissue-based
Next-Generation Sequencing (NGS) assays designed for harmonized
global use in research, clinical development, companion diagnostic
(CDx) development, and patient testing. With operational hubs in
Silicon Valley, Houston, Chicago, and Shanghai, Predicine
collaborates with leading biopharma companies, institutions, and
governments in personalized healthcare on a global scale. For more
information, please visit us on http://www.predicine.com and follow
us on LinkedIn or Twitter (X).
Contact Information:Predicine,
Inc.media@predicine.com